Fiche société
Northwestern University
Traitements, essais et publications liés.
Traitements29programmes
Essais13liés
Publications19liées
SourceDBlocale
Traitements
29| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ALDH2 Genetic Testing in East Asian CommunityThe goal of this clinical trial is to learn whether education plus genetic testing for ALDH2\*2 and ADH1B\*2 is feasible and acceptable and whether it influences modifiable health behaviors in East Asian American adults who experience alcohol flushing when they drink alcohol or have a family history of flushing. The main questions it aims to answer are: 1. Is providing education plus ALDH2\*2/ADH1B\*2 genetic testing feasible and acceptable in a clinical care context? 2. Does receiving genetic testing results plus education lead to changes in modifiable health behaviors compared with education alone? Researchers will compare education plus genetic testing (intervention arm) to education only (control arm) to see if adding genetic testing improves feasibility/acceptability and supports health behavior change. Participants will: 1. Complete an education module about alcohol flushing and ALDH2/ADH1B 2. Be randomized to either: (A) Receive genetic testing for ALDH2\*2 and ADH1B\*2 with results disclosure, or (B) Receive education only. 3. Complete follow-up measures about feasibility, acceptability, and modifiable health behaviors | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Aria SensorThe purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD. | Parkinson | Phase 3 | À vérifier | United States | À vérifier |
| BalstilimabBrain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune system. The device will be implanted after radiation is completed. Immune modulating drugs will be given every 3 weeks in conjunction with activation of the device to open the BBB. The objectives of this trial are to establish whether it is safe and feasible to administer immune modulating drugs in this manner, and identify whether the treatment is effective in treating glioblastoma. | Cancer | Phase 2 | United States | À vérifier | |
| BotensilimabBrain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune system. The device will be implanted after radiation is completed. Immune modulating drugs will be given every 3 weeks in conjunction with activation of the device to open the BBB. The objectives of this trial are to establish whether it is safe and feasible to administer immune modulating drugs in this manner, and identify whether the treatment is effective in treating glioblastoma. | Cancer | Phase 2 | United States | À vérifier | |
| Dynacirc CR (Isradipine)The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD. This study is a logical continuation of the project that is being completed now and is conducted in preparation to NIH submission of the pivotal study on the efficacy of this agent for neuroprotection in PD. This study is conducted in parallel with Dr. Surmeier's work on further development of the preclinical data. The focus of his work now is to establishing the correlation between the dose that demonstrated neuroprotective effect in animal model and the dose used for clinical practice. Hypothesis 1: Patients with PD will be able to tolerate isradipine across the FDA recommended dose range. We expect 10% attrition due to hypotensive effect of the agent. Hypothesis 2: Patients with PD and concomitant stable hypertension will be able to tolerate isradipine provided that the dose of the concomitant antihypertensive agent is adjusted based on the blood pressure reading. | Parkinson | Phase 2 | Neuroprotection | United States | À vérifier |
| Focal cortical coolingElectrocortical stimulation (ECS) mapping is a procedure used during brain surgeries, for example when treating diseases like epilepsy or when removing brain tumors. ECS mapping helps surgeons locate areas of the cerebral cortex (the outer part of the brain) that are important for everyday tasks like movement and speech. ECS mapping has been used for decades, and is considered the "gold-standard" tool for locating important areas of cortex. Despite this long history, there is still no clear understanding of exactly how ECS works. The goal of this study is to learn details about the effects ECS has on the brain. The main questions the study aims to answer are: 1) how ECS affects the neurons of the cortex at the stimulation site; and 2) how ECS impacts brain regions that are critically important for human speech and language. These so-called "critical sites" can be physically distant from one another on the brain's surface, requiring extensive ECS mapping and long surgeries. Critical sites are thought to be part of a speech/language network of brain areas, and so the study's goal is to learn about how they are connected. In some participants, the brain's surface will also be slightly cooled. This is a painless procedure that does not harm the brain's function, but could provide insight as to which parts of the brain (the surface, or deeper parts) are responsible for the effects of ECS. By improving the understanding of how ECS affects the brain and improving the ability to identify critical sites, this study could potentially lead to shorter surgeries and better outcomes for future individuals who need this care. Participants will be recruited from among individuals who are undergoing brain surgery for epilepsy treatment or tumor removal. Participants will complete simple tasks like reading words or naming pictures, similar to standard testing that is already performed during their hospital stay. | Épilepsie | Non applicable | Traitement symptomatique | United States | À vérifier |
| GLP-1The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score. | SEP | À vérifier | Ralentissement de la progression | United States | À vérifier |
| Hydroxychloroquine in Combination With Encorafenib and Cetuximab or PanitumumabThis is a Phase II, open label, single-arm trial study of adding hydroxychloroquine to encorafenib and cetuximab in patients with metastatic BRAF V600E colon cancer with progression on at least 1 prior line of therapy. We hypothesize that autophagy is a major mechanism of resistance to BRAF inhibition in stage IV BRAF V600E colorectal cancer, and that the addition of hydroxychloroquine to standard encorafenib and cetuximab therapy will help overcome this resistance. | Cancer | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's DiseaseClinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients. As a direct sound-based approach, CDIM does not rely on autobiographical memory and may have wider applicability and generalizability. We wish to examine if CDIM decreases anxiety in 15 cognitively healthy individuals and 15 Alzheimer Disease patients with anxiety (AD-A). | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Ocrelizumab (US)The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score. | SEP | À vérifier | Ralentissement de la progression | United States | À vérifier |
| Ocrevus ZunovoOcrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment. The purpose of this study is to synthesize implementation strategies that improve patient access to high-efficacy MS therapies in real-world settings. | SEP | À vérifier | À vérifier | United States | À vérifier |
| Over the counter hearing aidThe goal of this study is to better understand if, in patients with mild to moderate hearing loss who are also experiencing mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD), Over-the-Counter (OTC) hearing aids: 1. improve communication 2. Whether the magnitude of benefit depends on the patient's level of cognitive disability, 3. Whether alternative remediation (such as targeted communication strategies) offer similar benefits. Participants and a communication partner will be randomized into an OTC first or Communication Strategies first arm, where participants will receive communication strategy information customized for those with cognitive impairment. | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| PYL-AIP — Implementation of AIP Services for Older Adults With ADThis study will longitudinally follow a cohort of older adults to better understand how decisions about aging in place or transitioning to long-term care-and the implementation of those decisions-are influenced by age-related changes (e.g., cognition, health literacy, chronic conditions) and social supports (e.g., caregivers). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| SAGE LEAF 2: An Online Program to Reduce Dementia Caregiver BurdenThe goal of this clinical trial is to learn if the SAGE LEAF (Social Augmentation of self-Guided Electronic delivery of the Life Enhancing Activities for Family caregivers) online positive emotion skill-building program delivered through Caregiver Serving Organizations can help family caregivers of individuals with dementia cope with stress. The main questions it aims to answer are: * How does SAGE LEAF affect positive emotion, caregiver burden, loneliness, and depression for family caregivers? * What are the challenges and successes when rolling out an online program in partnership with Caregiver Serving Organizations? Participants will complete the 8-week online SAGE LEAF intervention as well as two survey assessments, one before the intervention and one after. | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Sonocloud-9 (SC-9)Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune system. The device will be implanted after radiation is completed. Immune modulating drugs will be given every 3 weeks in conjunction with activation of the device to open the BBB. The objectives of this trial are to establish whether it is safe and feasible to administer immune modulating drugs in this manner, and identify whether the treatment is effective in treating glioblastoma. | Cancer | Phase 2 | United States | À vérifier | |
| Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP)STEP-UP will promote linkage to primary care and ongoing chronic disease evaluation for postpartum women with prior gestational diabetes mellitus (GDM) and/or hypertensive disorders of pregnancy (HDP). | Hypertension | Phase 3 | À vérifier | United States | À vérifier |
| GLP-1The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score. | SEP | À vérifier | Ralentissement de la progression | United States | À vérifier |
| Hydroxychloroquine in Combination With Encorafenib and Cetuximab or PanitumumabThis is a Phase II, open label, single-arm trial study of adding hydroxychloroquine to encorafenib and cetuximab in patients with metastatic BRAF V600E colon cancer with progression on at least 1 prior line of therapy. We hypothesize that autophagy is a major mechanism of resistance to BRAF inhibition in stage IV BRAF V600E colorectal cancer, and that the addition of hydroxychloroquine to standard encorafenib and cetuximab therapy will help overcome this resistance. | Cancer | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| Ocrevus ZunovoOcrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment. The purpose of this study is to synthesize implementation strategies that improve patient access to high-efficacy MS therapies in real-world settings. | SEP | À vérifier | À vérifier | United States | À vérifier |
| ALDH2 Genetic Testing in East Asian CommunityThe goal of this clinical trial is to learn whether education plus genetic testing for ALDH2\*2 and ADH1B\*2 is feasible and acceptable and whether it influences modifiable health behaviors in East Asian American adults who experience alcohol flushing when they drink alcohol or have a family history of flushing. The main questions it aims to answer are: 1. Is providing education plus ALDH2\*2/ADH1B\*2 genetic testing feasible and acceptable in a clinical care context? 2. Does receiving genetic testing results plus education lead to changes in modifiable health behaviors compared with education alone? Researchers will compare education plus genetic testing (intervention arm) to education only (control arm) to see if adding genetic testing improves feasibility/acceptability and supports health behavior change. Participants will: 1. Complete an education module about alcohol flushing and ALDH2/ADH1B 2. Be randomized to either: (A) Receive genetic testing for ALDH2\*2 and ADH1B\*2 with results disclosure, or (B) Receive education only. 3. Complete follow-up measures about feasibility, acceptability, and modifiable health behaviors | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's DiseaseClinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients. As a direct sound-based approach, CDIM does not rely on autobiographical memory and may have wider applicability and generalizability. We wish to examine if CDIM decreases anxiety in 15 cognitively healthy individuals and 15 Alzheimer Disease patients with anxiety (AD-A). | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Focal cortical coolingElectrocortical stimulation (ECS) mapping is a procedure used during brain surgeries, for example when treating diseases like epilepsy or when removing brain tumors. ECS mapping helps surgeons locate areas of the cerebral cortex (the outer part of the brain) that are important for everyday tasks like movement and speech. ECS mapping has been used for decades, and is considered the "gold-standard" tool for locating important areas of cortex. Despite this long history, there is still no clear understanding of exactly how ECS works. The goal of this study is to learn details about the effects ECS has on the brain. The main questions the study aims to answer are: 1) how ECS affects the neurons of the cortex at the stimulation site; and 2) how ECS impacts brain regions that are critically important for human speech and language. These so-called "critical sites" can be physically distant from one another on the brain's surface, requiring extensive ECS mapping and long surgeries. Critical sites are thought to be part of a speech/language network of brain areas, and so the study's goal is to learn about how they are connected. In some participants, the brain's surface will also be slightly cooled. This is a painless procedure that does not harm the brain's function, but could provide insight as to which parts of the brain (the surface, or deeper parts) are responsible for the effects of ECS. By improving the understanding of how ECS affects the brain and improving the ability to identify critical sites, this study could potentially lead to shorter surgeries and better outcomes for future individuals who need this care. Participants will be recruited from among individuals who are undergoing brain surgery for epilepsy treatment or tumor removal. Participants will complete simple tasks like reading words or naming pictures, similar to standard testing that is already performed during their hospital stay. | Épilepsie | Non applicable | Traitement symptomatique | United States | À vérifier |
| SAGE LEAF 2: An Online Program to Reduce Dementia Caregiver BurdenThe goal of this clinical trial is to learn if the SAGE LEAF (Social Augmentation of self-Guided Electronic delivery of the Life Enhancing Activities for Family caregivers) online positive emotion skill-building program delivered through Caregiver Serving Organizations can help family caregivers of individuals with dementia cope with stress. The main questions it aims to answer are: * How does SAGE LEAF affect positive emotion, caregiver burden, loneliness, and depression for family caregivers? * What are the challenges and successes when rolling out an online program in partnership with Caregiver Serving Organizations? Participants will complete the 8-week online SAGE LEAF intervention as well as two survey assessments, one before the intervention and one after. | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Over the counter hearing aidThe goal of this study is to better understand if, in patients with mild to moderate hearing loss who are also experiencing mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD), Over-the-Counter (OTC) hearing aids: 1. improve communication 2. Whether the magnitude of benefit depends on the patient's level of cognitive disability, 3. Whether alternative remediation (such as targeted communication strategies) offer similar benefits. Participants and a communication partner will be randomized into an OTC first or Communication Strategies first arm, where participants will receive communication strategy information customized for those with cognitive impairment. | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| BalstilimabBrain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune system. The device will be implanted after radiation is completed. Immune modulating drugs will be given every 3 weeks in conjunction with activation of the device to open the BBB. The objectives of this trial are to establish whether it is safe and feasible to administer immune modulating drugs in this manner, and identify whether the treatment is effective in treating glioblastoma. | Cancer | Phase 2 | United States | À vérifier | |
| Aria SensorThe purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD. | Parkinson | Phase 3 | À vérifier | United States | À vérifier |
| Dynacirc CR (Isradipine)The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD. This study is a logical continuation of the project that is being completed now and is conducted in preparation to NIH submission of the pivotal study on the efficacy of this agent for neuroprotection in PD. This study is conducted in parallel with Dr. Surmeier's work on further development of the preclinical data. The focus of his work now is to establishing the correlation between the dose that demonstrated neuroprotective effect in animal model and the dose used for clinical practice. Hypothesis 1: Patients with PD will be able to tolerate isradipine across the FDA recommended dose range. We expect 10% attrition due to hypotensive effect of the agent. Hypothesis 2: Patients with PD and concomitant stable hypertension will be able to tolerate isradipine provided that the dose of the concomitant antihypertensive agent is adjusted based on the blood pressure reading. | Parkinson | Phase 2 | Neuroprotection | United States | À vérifier |
| Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP)STEP-UP will promote linkage to primary care and ongoing chronic disease evaluation for postpartum women with prior gestational diabetes mellitus (GDM) and/or hypertensive disorders of pregnancy (HDP). | Hypertension | Phase 3 | À vérifier | United States | À vérifier |
| PYL-AIP — Implementation of AIP Services for Older Adults With ADThis study will longitudinally follow a cohort of older adults to better understand how decisions about aging in place or transitioning to long-term care-and the implementation of those decisions-are influenced by age-related changes (e.g., cognition, health literacy, chronic conditions) and social supports (e.g., caregivers). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
Essais cliniques
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| PYL-AIP — Implementation of AIP Services for Older Adults With AD | Alzheimer | À vérifier | NCT07361601 | PYL-AIP — Implementation of AIP Services for Older Adults With AD | WITHDRAWN |
| Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) | Hypertension | Phase 3 | NCT05852054 | Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) | COMPLETED |
| Dynacirc CR (Isradipine) | Parkinson | Phase 2 | NCT00753636 | Parkinson's Disease Isradipine Safety Study | COMPLETED |
| Aria Sensor | Parkinson | Phase 3 | NCT04664634 | A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's | RECRUITING |
| Balstilimab | Cancer | Phase 2 | NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | RECRUITING |
| Over the counter hearing aid | Alzheimer | Non applicable | NCT06112860 | OTC Hearing Aid and MCI | RECRUITING |
| SAGE LEAF 2: An Online Program to Reduce Dementia Caregiver Burden | Alzheimer | Non applicable | NCT06708182 | SAGE LEAF 2: An Online Program to Reduce Dementia Caregiver Burden | COMPLETED |
| Focal cortical cooling | Épilepsie | Non applicable | NCT06391294 | Neuronal and Network Mechanisms of Electrocortical Stimulation | ENROLLING_BY_INVITATION |
| Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease | Alzheimer | Non applicable | NCT05477862 | Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease | ENROLLING_BY_INVITATION |
| ALDH2 Genetic Testing in East Asian Community | Alzheimer | Non applicable | NCT07392775 | ALDH2 Genetic Testing in East Asian Community | NOT_YET_RECRUITING |
| Ocrevus Zunovo | SEP | À vérifier | NCT07710105 | Ocrevus Zunovo for MS: Mixed Methods | RECRUITING |
| Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab | Cancer | Phase 2 | NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | TERMINATED |
| GLP-1 | SEP | À vérifier | NCT07207148 | People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | RECRUITING |
Publications
19| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Focal cortical cooling | Brain Temperature Alters Contributions of Excitatory and Inhibitory Inputs to Evoked Field Potentials in the Rat Frontal Cortex. | Frontiers in cellular neuroscience | ||
| Focal cortical cooling | Focal Cortical Surface Cooling is a Novel and Safe Method for Intraoperative Functional Brain Mapping. | World neurosurgery | ||
| Focal cortical cooling | Effects of focal cortical cooling on somatosensory evoked potentials in rats. | Brain research | ||
| Balstilimab | WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. | Oncotarget | ||
| Balstilimab | Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. | Oncogene | ||
| Balstilimab | Immunotherapy in Colorectal Cancer: Novel Perspectives and Next Steps. | American journal of clinical oncology | ||
| Ocrelizumab (US) | Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis. | Neurology and therapy | ||
| Ocrelizumab (US) | Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. | Journal of neurology, neurosurgery, and psychiatry | ||
| GLP-1 | reduces kynurenine levels and alleviates obesity and related metabolic disorders in model mice. | Gut microbes | ||
| GLP-1 | Peptide LKLKLL is a more effective component of which regulate glucolipid metabolism through GLP-1/GIP dual modulation. | Gut microbes | ||
| GLP-1 | Mulberry leaf flavonoids alleviate type 2 diabetes by remodeling the gut microbiota-bile acid axis and activating FXR signaling. | Journal of ethnopharmacology | ||
| Ocrevus Zunovo | In brief: Subcutaneous ocrelizumab (Ocrevus Zunovo) for multiple sclerosis. | The Medical letter on drugs and therapeutics | ||
| Ocrevus Zunovo | Findings from the 2025 AMCP Foundation Symposium: Health Optimization 2.0. | Journal of managed care & specialty pharmacy | ||
| GLP-1 | Anti-Obesity Medications in Longevity and Aesthetic Medicine. | Journal of clinical medicine | ||
| GLP-1 | Public Policies in Historical Context and the Association Between Education and US Older Adults' Health. | The Milbank quarterly | ||
| Ocrelizumab (US) | Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis. | Journal of medical economics | ||
| Ocrelizumab (US) | Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial. | Annals of neurology | ||
| GLP-1 | Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | ||
| GLP-1 | Hyodeoxycholic acid suppresses hepatic steatosis in a PPARα-dependent manner via distinct GLP-1- and iNKT cell-mediated pathways. | Cell reports |